North America
Europe
Denmark
France
Germany
Italy
Netherlands
Poland
Spain
Sweden
Switzerland
U.K.
Latin America
Asia Pacific
Argentina
Brazil
Mexico
Australia
China
Hong Kong
India
Japan
Korea
New Zealand
Singapore
Taiwan
今まで以上に規模を拡大して内容を充実させたULのグローバル調査。製造者と消費者の態度や優先順位にどのような差異が見られるかを、様々な製品関連の検討要因にわたって精査します。

詳細を見る >
ULは、4つの基本分野全体にわたる基本的な発見、試験方法、ソフトウェア、規格を通して、世界をより安全にしていくための重要な方法を示す強力な取り組みであるNew Scienceをお届けしていることを誇りとしています。

詳細を見る >

規格

弊社の厳格な要件に基づいて、毎年何千点もの製品やコンポーネントに対する試験が行われています。

ダッシュボード

これまで以上にスマートで効率的かつ高速になったULのダッシュボードツールは、進化し続けるマーケットニーズを満たしていく企業のお役に立ちます。

詳細を見る >

LIBRARY

MARKS HUB

SERVICES

STANDARDS

Share

FDA 510(k) third-party review

A 510(k) is a premarketing submission made to the FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device that is not subject to premarket approval (PMA). 510(k) (premarket notification) to the FDA is required at least 90 days before marketing, unless the device is exempt from 510(k) requirements.

Who has to submit a 510(k)?

Manufacturers must submit a new 510(k) when introducing a device into commercial distribution for the first time, proposing a different intended use for a medical device from that which they already have in commercial distribution, or if they wish to modify a device already on the market in a way that could significantly affect its safety or effectiveness.

What is third-party review?

To improve the efficiency of the 510(k) process, the FDA created the Accredited Persons Program, which authorized third parties to conduct the primary review of 510(k)s for most eligible devices. As an Accredited Person, UL is able to review a manufacturer's 510(k) information and offer a recommendation to the FDA as to whether the device is substantially equivalent to other legally marketed devices (predicate devices) in the United States. The FDA will then determine whether to grant market clearance. UL is accredited to review 510(k)s for all devices eligible under the Accredited Persons Program.

The UL advantage

UL has been an Accredited Person since program inception.   UL's experience in providing the 510(k) service is one reason why so many global medical device manufacturers have come to UL as their preferred 510(k) reviewer.

  • Time -- By law, the FDA must take action on a submission from an Accredited Person within 30 days compared to the 90 days the FDA can take to respond to a direct submission.
  • Money -- FDA user fees only apply for direct submissions. 
  • Expertise -- UL has completed more reviews than any other Accredited Person since program inception.

Additional Resources

  • "510(k) Accredited Persons Program" Article Reprint available for download on UL Knowledge Services Thought Leadership pages under "Health Sciences."
  • Download UL's FDA 510(k) toolkit, which contains helpful checklists and resources to help you get your 510(k) ready for submission (registration required)
  • Download white paper on the Accredited Person's Program by Harvey Rudolph, Ph.D. (registration required)